AstraZeneca breast cancer medicine slows disease by over six months
AstraZeneca's new breast cancer pill, Camizestrant, shows promising results. The drug delayed cancer progression by over six months in trials. Camizestrant, combined with other medicines, helped patients live longer without cancer worsening. AstraZeneca hopes this data will establish a new treatment approach. The company anticipates significant sales, though analysts offer more conservative estimates.
Tired of too many ads?
Remove Ads
New York: AstraZeneca Plc's experimental breast cancer pill delayed disease progression by over six months, according to data from a new study that is likely to capture investors' attention. Camizestrant , in combination with other cancer medicines, helped patients with a specific type of breast cancer to live for a median of 16 months without their cancer progressing, compared with 9.2 months for those taking the current standard treatment.Astra hopes the study data, presented at the American Society of Clinical Oncology's annual meeting in Chicago, will help establish a new treatment strategy for some breast cancer patients.Camizestrant works as a hormone therapy to stop estrogen from attaching to cancer cells and helping them to grow.When other potential uses for camizestrant are taken into account, Astra believes the drug could bring in over $5 billion in annual sales. But analysts are more cautious as other similar drugs have failed, with Barclays estimating potential peak year sales at $3.6 billion. AstraZeneca has established itself as a cancer drug powerhouse under CEO Pascal Soriot, with medicines including Tagrisso and Imfinzi fueling growth.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
18 hours ago
- Mint
Exercise more effective than drugs in lowering 37% cancer deaths, 28% recurrence, shows new international trial
A groundbreaking international trial involving patients from the US, UK, Australia, France, Canada, and Israel has discovered that following a structured exercise programme after treatment can significantly lower the risk of cancer deaths by third, recurrence, or the development of a new cancer and is even more effective than drugs, The Guardian reported. Patients who started a structured exercise program with the support of a personal trainer or health coach after finishing treatment experienced a 37% lower risk of death and a 28% reduced risk of cancer recurrence or new cancers, compared to those who received only health advice, the trial found. The findings were revealed in Chicago at the American Society of Clinical Oncology (ASCO) annual meeting, the world's largest cancer conference, and published in the New England Journal of Medicine. For the first time in medical history, there is clear evidence that exercise surpasses many commonly prescribed medications in preventing cancer recurrence and death, according to one of the world's leading cancer specialists. In the trial, researchers enrolled 889 colon cancer patients from 2009 to 2023, with the majority (90%) diagnosed with stage three disease. Patients were randomly assigned to participate in a structured exercise programme (445) or to just get a healthy lifestyle booklet (444). Patients in the exercise group met with a personal trainer twice a month for coaching and supervised workouts, later reducing to once a month, continuing this routine for a total of three years. The exercise group received coaching and support to help them reach specific exercise goals. Their weekly target was the equivalent of three to four walks lasting 45 to 60 minutes each, though patients were free to choose their preferred activities, some opted for kayaking or skiing, for example. After five years, those in the exercise group showed a 28% lower risk of cancer recurrence or new cancers compared to the control group. After eight years, they also had a 37% lower risk of death than patients who only received the healthy lifestyle booklet. Dr. Julie Gralow, Chief Medical Officer of ASCO and not involved in the decade-long study, described the quality of the findings as the 'highest level of evidence' and stated that they would bring about 'a major shift in recognising the importance of promoting physical activity during and after treatment.' 'We titled [the session it was presented in] As Good as a Drug. I would have retitled it Better than a Drug, because you don't have all the side-effects. It's the same magnitude of benefit of many drugs that get approved for this kind of magnitude of benefit – 28% decreased risk of occurrence, 37% decreased risk of death. Drugs get approved for less than that, and they're expensive and they're toxic. When I started three decades ago it was still the era where we'd be gentle and say, don't overdo yourself when you're on chemo. We've reversed that. I would say [exercise is] better than a drug,' The Guardian quoted her as saying.
Time of India
a day ago
- Time of India
Evidence of CAR T-cell therapy against cancers presented at US conference
New Delhi: Studies have provided evidence of the effectiveness of CAR T-cell therapy against gastric and brain tumours. The papers, presented at the annual meeting of the American Society of Clinical Oncology [ASCO] 2025, held from May 30 to June 3 in Chicago, US, have also been published in journals, including The Lancet and Nature Medicine. Treating cancer using CAR T-cell therapy involves modifying genes in one's T-cells - a type of immune cell - to help fight cancer. In The Lancet paper, that revealed results of phase 2 clinical trials , 156 patients with advanced gastric or gastro-oesophageal junction cancer - and who were resistant to "at least two previous lines of treatment" - were randomly assigned to receive 'satri-cel' or an intervention of physician's choice. Satri-cel, or 'Satricabtagene autoleucel' - a CAR T-cell therapy -- showed "encouraging activity" in phase 1 clinical trials in treating patients with advanced gastric or gastro-oesophageal junction cancer, the team, including researchers from China's Peking University Cancer Hospital and Institute, said. A phase-1 trial primarily looks at establishing a new drug's safety and dose characteristics in about 20-100 healthy volunteers, while a 'phase-2' trial provides evidence of the effectiveness of the experimental drug in about 100-300 volunteers or participants. "In this multicentre, randomised, phase 2 study, satri-cel was associated with a statistically significant increase in progression-free survival and clinically meaningful increase in overall survival compared with TPC (treatment of physician's choice), along with a manageable safety profile in patients," the authors wrote. They added that it is the "first randomised controlled study of a CAR T-cell therapy in solid tumours". In the second study, published in the Nature Medicine journal, researchers from the University of Pennsylvania, US, said that CAR T-cell therapy "shows promise for slowing tumour growth in a notoriously aggressive and fast-growing brain cancer ". The phase-1 trial involved 18 patients with glioblastoma who received the treatment. "Tumour regression (becoming smaller) occurred in eight of 13 patients (62 per cent) with measurable disease," the authors wrote. In March, a CAR T-cell therapy, indigenously developed by researchers from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, showed a 73 per cent response rate in patients of leukaemia and lymphoma, who either relapsed following a period of remission or were resistant to treatment. The results of the phase 1 and 2 clinical trials are published in The Lancet Haematology journal. PTI
The Hindu
2 days ago
- The Hindu
Evidence of CAR T-cell therapy against cancers presented at US conference
Studies have provided evidence of the effectiveness of CAR T-cell therapy against gastric and brain tumours. The papers, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) 2025, held from May 30 to June 3 in Chicago, US, have also been published in journals, including The Lancet and Nature Medicine. Treating cancer using CAR T-cell therapy involves modifying genes in one's T-cells – a type of immune cell – to help fight cancer. In The Lancet paper, that revealed results of phase 2 clinical trials, 156 patients with advanced gastric or gastro-oesophageal junction cancer – and who were resistant to 'at least two previous lines of treatment' – were randomly assigned to receive 'satri-cel' or an intervention of physician's choice. Satri-cel, or 'Satricabtagene autoleucel' – a CAR T-cell therapy -- showed 'encouraging activity' in phase 1 clinical trials in treating patients with advanced gastric or gastro-oesophageal junction cancer, the team, including researchers from China's Peking University Cancer Hospital and Institute, said. A phase-1 trial primarily looks at establishing a new drug's safety and dose characteristics in about 20-100 healthy volunteers, while a 'phase-2' trial provides evidence of the effectiveness of the experimental drug in about 100-300 volunteers or participants. 'In this multicentre, randomised, phase 2 study, satri-cel was associated with a statistically significant increase in progression-free survival and clinically meaningful increase in overall survival compared with TPC (treatment of physician's choice), along with a manageable safety profile in patients,' the authors wrote. They added that it is the 'first randomised controlled study of a CAR T-cell therapy in solid tumours'. In the second study, published in the Nature Medicine journal, researchers from the University of Pennsylvania, US, said that CAR T-cell therapy 'shows promise for slowing tumour growth in a notoriously aggressive and fast-growing brain cancer'. The phase-1 trial involved 18 patients with glioblastoma who received the treatment. 'Tumour regression (becoming smaller) occurred in eight of 13 patients (62 per cent) with measurable disease,' the authors wrote. In March, a CAR T-cell therapy, indigenously developed by researchers from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, showed a 73 per cent response rate in patients of leukaemia and lymphoma, who either relapsed following a period of remission or were resistant to treatment. The results of the phase 1 and 2 clinical trials are published in The Lancet Haematology journal.
